More articles from Letters to the editor

  • Antiobesity drug therapy
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 657; DOI: https://doi.org/10.3949/ccjm.88c.12001
  • Physician resistance to obesity pharmacotherapy
    Vania Modesto-Lowe, MD, Allison Wick, BS and Michael Dang, BS, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 658; DOI: https://doi.org/10.3949/ccjm.88c.12003
  • In Reply: Antiobesity drug therapy
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta Kashyap, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 657-658; DOI: https://doi.org/10.3949/ccjm.88c.12002
  • In Reply: Physician resistance to obesity pharmacotherapy
    Yael Mauer, MD, MPH, Marcie Parker, PharmD, BCACP and Sangeeta Kashyap, MD
    Cleveland Clinic Journal of Medicine December 2021, 88 (12) 658-659; DOI: https://doi.org/10.3949/ccjm.88c.12004
  • In Reply: Prostate cancer screening
    Prasanna Sooriakumaran, MD, PhD, FRCSUrol, FEBU
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 261; DOI: https://doi.org/10.3949/ccjm.88c.05003

    Detection does not lead to overtreatment.

  • Prostate cancer screening
    Sherry Zhang, MD and Ian Jenkins, MD
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: https://doi.org/10.3949/ccjm.88c.05001

    The costs of PSA testing—both financial and to the patient’s well-being—are not worth it.

  • Prostate cancer screening
    Kevin Kurator, BS, BA and Ian Jenkins, MD
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 260; DOI: https://doi.org/10.3949/ccjm.88c.05002

    Screening should be advised only if benefits clearly outweigh the risks

  • In Reply: Prostate cancer screening
    Timothy Gilligan, MD
    Cleveland Clinic Journal of Medicine May 2021, 88 (5) 262; DOI: https://doi.org/10.3949/ccjm.88c.05004

    The debate about screening remains fraught, and passions run high on both sides.

  • In Reply: Assessing stable coronaryartery disease
    Vinayak Nagaraja, MD and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 714; DOI: https://doi.org/10.3949/ccjm.87c.12004

    CT angiography is the appropriate test to exclude left main disease.

  • In Reply: COVID-19 coagulopathy
    Simon R. Mucha, MD, Siddharth Dugar, MD, Keith McCrae, MD, Douglas Joseph, DO, John Bartholomew, MD, Gretchen L. Sacha, PharmD, RPh, BCCCP and Michael Militello, PharmD, RPh, BCPS
    Cleveland Clinic Journal of Medicine December 2020, 87 (12) 712; DOI: https://doi.org/10.3949/cjm.87c.12002

    An attempt to balance the potential risks and benefits of intensified prophylaxis.

Pages